The European EprObes project, which uses a methodology based on Artificial Intelligence, will study how to prevent obesity through early identification of biomarkers, risk factors, prognosis and intervention.
IDIBELL participates in a €10M European project to prevent childhood obesity Read More »
The project, promoted by IDIBELL and CNIO, together with seven other research institutes, will combine artificial intelligence with cutting-edge molecular biology techniques to provide predictive medicine tools to the National Health Service.
3.2 million euros to identify new genetic variants responsible for hereditary cancers Read More »
The journal New England Journal of Medicine has published the results of the NADIM II study, which confirms the great benefit of chemo-immunotherapy with nivolumab before surgery on locally advanced tumors and is consolidated worldwide as the standard of treatment.
This is a relevant position, endorsed by the scientific and care trajectory of Dr. Maria Molina, head of the Pneumology research group of the Institute of Bellvitge Biomedical Research.
The results of the study led by IDIBELL and the Hospital de Bellvitge solve a pending issue and open new ways to improve the patients’ life quality with safe and effective treatment.
The coordinator of the IDIBELL Systemic, Vascular and Aging Diseases group will be globally responsible, together with two other editors, for the section on Rare Cardiovascular Diseases of the Orphanet Journal of Rare Diseases.
Funded by the European Union, the project aims to develop, evaluate and disseminate a methodological implementation framework for cancer known as the ‘Integrated Implementation Kit’ in six risk factors, such as tobacco, alcohol, ‘sun exposure, the human papilloma virus, nutrition and physical activity.
The American Journal of Gastrointestinal Endoscopy published a multicenter study on the treatment of gastrointestinal subepithelial tumors led by the Bellvitge Biomedical Research Institute (IDIBELL) and the Digestive Endoscopy Unit of the Bellvitge University Hospital (HUB).
The objective was to select non-invasive biomarkers with diagnostic and prognostic utility, which allow the identification of individuals with a real possibility of recovering sperm from a testicular biopsy, necessary for assisted reproduction treatment.
Small RNAs in semen are useful biomarkers to determine the origin of azoospermia Read More »
This past June 9 and 10, NeuroDebate took place, a conference promoted by the Bellvitge University Hospital (HUB), the Bellvitge Biomedical Research Institute (IDIBELL) and the University of Barcelona.
